GTCM
ALGS icon

Gyon Technologies Capital Management’s Aligos Therapeutics ALGS Stock Holding History

Gyon Technologies Capital Management’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-622
Closed -$185K – 276
2021
Q4 		$185K Buy
+622
New +$227K 0.03% 531
2021
Q2 		– Sell
-436
Closed -$248K – 347
2021
Q1 		$248K Buy
+436
New +$290K 0.11% 331

Other funds holding ALGS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Gyon Technologies Capital Management's ALGS Position: Q1 2022 in Review

Gyon Technologies Capital Management sold out of Aligos Therapeutics (ALGS) in Q1 2022, closing a stake of 622 shares — an estimated $185K sold.

Gyon Technologies Capital Management first reported a position in ALGS in Q1 2021 and held it in 2 quarters. The position peaked at $248K in Q1 2021. 76 funds tracked by Wall St. Rank hold ALGS as of Q1 2022.

  • Gyon Technologies Capital Management reported no remaining Aligos Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Gyon Technologies Capital Management sold 622 Aligos Therapeutics shares in Q1 2022, an estimated $185K.
  • Gyon Technologies Capital Management first reported a position in Aligos Therapeutics in Q1 2021 and held it in 2 quarters.
  • Gyon Technologies Capital Management's Aligos Therapeutics position peaked at $248K in Q1 2021.
  • 76 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q1 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2022, filed 12 May 2022.